NGS launches clinical trial on supplements for young athletes. Image: Getty.
Health & Biotech
NGS has formulated a nutritional supplement for young athletes as it targets the lucrative sports nutrition market.
Nutritional Growth Solutions (ASX:NGS) has commenced a clinical trial to evaluate the effect of its innovative sports supplement on the physical activity performance of young soccer players.
The paediatric nutritional products provider has formulated a nutritional supplement to help adolescent athletes improve their body composition, exercise performance, and general health.
The clinical trial will be conducted on 50 healthy soccer players aged 8-15 years old to determine efficacy and safety of the new supplement versus placebo.
It comprises an 8-week treatment period followed by an 8-week open-label period, with initial results expected in Q3 2023.
“This trial marks our first step into the growing sports supplements market, and we look forward to offering active children a safe, effective supplement, which was designed especially for them,” commented CEO, Liron Fendell.
The global sports nutrition market and supplements was valued at US$44.43 billion in 2021 and is expected to surge in value to US$85.7 billion by 2030.
NGS says its innovative nutritional supplement supplies a boost of nutritious energy for young athletes.
The supplement contains high quality whey proteins, amino acids, creatine monohydrate, carbohydrates, fats, and micronutrients (including calcium, iron, zinc, magnesium, vitamin A, vitamin C, vitamin D, vitamin E and vitamin B complex).
Research has shown that lacking sufficient calories, macro as well as micro-nutrients may impair an athlete’s training adaptations.
On the other hand, athletes who consume a balanced diet that meets energy needs can enhance physiological training adaptations.
“Based on extensive research, NGS has formulated an innovative nutritional supplement, aimed at completion of the high nutritional requirements of adolescent athletes to help them improve their body composition, exercise performance and general health,” said Fendell.
Research also shows that maintaining an energy and nutrient deficient diet during training may lead to loss of muscle mass, strength, and bone mineral density.
In addition, young athletes will be exposed to an increased susceptibility to illness and injuries, disturbances in immune, endocrine and reproductive function, and an increased prevalence of overreaching and/or overtraining without consuming proper nutrition.
Incorporating good dietary practices as part of a training program is one way to help optimise training adaptations and prevent overtraining, NGS said.
In the current trial, NGS will run multiple tests, including: 10m and 20m sprints, countermovement jumps, agility tests, endurance tests, anthropometric assessments (height, weight and BMI) and body composition.
While sales of existing products in the US continues to be the company’s focus in 2023, Fendell said NGS will invest up to $100k in this clinical trial.
“We’re continuing to build a strong pipeline of innovative, exciting products which we could sell through our existing and additional distribution channels in 2023,” he said.
“We’re looking forward to updating the market on both additional sales in the US and internationally as well as on the progress of the clinical trials over the coming weeks.”
This article was developed in collaboration with Nutritional Growth Solutions, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Health & Biotech
Health & Biotech
Health & Biotech
Get the latest Stockhead news delivered free to your inbox.
